CRP and myocardial infarction: That trial evaluated the efficacy of the interleukin-1β-blocking antibody canakinumab in more than 10,000 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter on nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death.